As shown in Fig. 7b-d, in our DCIS.COM MIND xenografts there was a significant increase in E-cadherin expression in BCL9 KD compared to the control (681,207 ± 198,349 U compared to 120,994 ± 25,258 U; p <0.05) and a significant reduction in vimentin expression in BCL9 KD compared to control (44,967 ± 5,402 U compared to 400,345 ± 111,633 U; p <0.05). The gene discussed is BCL9; the disease is ductal breast carcinoma in situ.